Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Procrit for Peri-Operative Transfusion Reduction in Orthopedic Surgery
NCT00270088Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 1993
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa in anemia (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Proportion of patients requiring blood transfusion. Started Apr 1993; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00270088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270088.